“…However, more than 60 ADCs are at different stages of development for use in breast cancer patients, including several trials for TNBC, with molecular targets such as TROP-2, LIV-1, HER2, HER3 and ROR2, amongst others. The selected agents included in this review are trastuzumab deruxtecan (T-DXd) (NCT04556773), ladiratuzumab vedotin (SGN-LIV1a) (NCT03310957), vic-trastuzumab duocarmazine (SYD985) (NCT04602117), anti-B7-H3-ADC (MGC018) (NCT03729596), CAB-ROR-ADC (BA3021) (NCT03504488), datopotamab deruxtecan (DS-1062) (NCT05374512) and tusamitamab Ravtansine (SAR408701) (NCT04659603) [22] (Table 2). Abbreviations: Progression-free survival (PFS), overall survival (OS), response rate (RR), percentage of participants with adverse events (AEs), serious adverse events (SAEs), overall response rate (ORR), duration of response (DOR), clinical benefit rate (CBR), disease control rate (DCR), maximum tolerated dose (MTD), recommended phase II dose (RP2D), best overall response (OR), event-free survival (EFS), time-to-treatment failure (TTF), time to objective response (TTOR) and time to response (TTR).…”